Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Statin Intolerance: the Clinician's Perspective

T. Stulc, R. Ceška, AM. Gotto,

. 2015 ; 17 (12) : 69.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Grant support
NT12217 MZ0 CEP Register

Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020205
003      
CZ-PrNML
005      
20190821135603.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11883-015-0552-3 $2 doi
024    7_
$a 10.1007/s11883-015-0552-3 $2 doi
035    __
$a (PubMed)26490078
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Štulc, Tomáš, $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, CZ 128 21, Praha 2 / Prague, Czech Republic. TSTULC@LF1.CUNI.CZ. $d 1965- $7 xx0056711
245    10
$a Statin Intolerance: the Clinician's Perspective / $c T. Stulc, R. Ceška, AM. Gotto,
520    9_
$a Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.
650    _2
$a kardiovaskulární nemoci $x farmakoterapie $7 D002318
650    _2
$a tolerance léku $7 D004361
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D019161
650    _2
$a hyperlipidemie $x farmakoterapie $7 D006949
650    _2
$a myalgie $x chemicky indukované $7 D063806
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Češka, Richard, $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, CZ 128 21, Praha 2 / Prague, Czech Republic. $d 1957- $7 nlk19990074195
700    1_
$a Gotto, Antonio M $u Weill Cornell Medical College, New York, 1305 York Avenue, Y-807, New York, NY, 10021, USA.
773    0_
$w MED00186151 $t Current atherosclerosis reports $x 1534-6242 $g Roč. 17, č. 12 (2015), s. 69
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26490078 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20190821135840 $b ABA008
999    __
$a ok $b bmc $g 1154875 $s 944733
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 17 $c 12 $d 69 $i 1534-6242 $m Current atherosclerosis reports $n Curr Atheroscler Rep $x MED00186151
GRA    __
$a NT12217 $p MZ0
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...